Sign In
Buy EPP
$56.50
-0.720 (-1.26%)
At Close: Jul 31, 2026
MESH project gains traction with Siemens Energy - ICYMI
03:11am, Saturday, 26'th Jul 2025
EnergyPathways PLC (AIM:EPP) CEO Ben Clube talked with Proactive about a new collaboration with Siemens Energy to advance the MESH integrated energy storage project. This marks a significant milestone
EnergyPathways shares surge 53% on Siemens Energy partnership for MESH project
09:02am, Monday, 21'st Jul 2025
Shares in EnergyPathways PLC (AIM:EPP) soared as much as 53% in afternoon trading on Monday after the company revealed Siemens Energy will lead a feasibility study for its flagship MESH energy storage
EnergyPathways brings on board Siemens Energy to advance UK's largest integrated energy storage project
08:17am, Monday, 21'st Jul 2025
EnergyPathways PLC (AIM:EPP) has taken a significant step in its drive to become a leader in grid-scale energy storage, announcing Siemens Energy will conduct a feasibility assessment for its flagshi
EPP: Searching For Yield And Stability
06:37am, Saturday, 29'th Mar 2025
The iShares MSCI Pacific Ex. Japan ETF (EPP) invests in over 90 companies in developed Pacific markets, excluding Japan, with a 0.48% management fee. This ETF offers a 3.7% dividend yield and lower va
WATERTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
07:00pm, Monday, 20'th Jan 2025
WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
04:01pm, Friday, 01'st Nov 2024
WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
07:07pm, Monday, 30'th Sep 2024
MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotid
Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress
01:26pm, Friday, 14'th Jun 2024
Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using b
Hong Kong regulators approve launch of spot bitcoin and ether ETFs
08:45am, Monday, 15'th Apr 2024
Hong Kong regulators on Monday approved the launch of spot bitcoin and ether exchange-traded funds (ETFs), asset managers said.
Bitcoin And Ether Climb As Firms Approve Crypto ETFs In Hong Kong
06:28am, Monday, 15'th Apr 2024
Hong Kong has authorized its first exchange-traded funds tracking digital assets bitcoin and ether, according to statements from multiple issuers on Monday, boosting the wider market and making the ci
Hong Kong gives initial approval to first bitcoin, ether spot ETFs, say funds
05:38am, Monday, 15'th Apr 2024
Hong Kong conditionally approved its first spot bitcoin and ether exchange traded funds (ETFs) on Monday, money managers said, paving the way for the city to become Asia's first to accept the cryptocu
Hong Kong set to approve its first spot bitcoin ETFs in April, sources say
04:26am, Wednesday, 10'th Apr 2024
Spot bitcoin exchange-traded funds could be launched in Hong Kong this month with the first approvals likely to be announced next week, two people familiar with the matter said.
Asia-Pacific Is Not Just China
12:30pm, Friday, 09'th Feb 2024
While the China macro story of ongoing transition is a headwind to the rest of Asia, there is more to the region's economic health than this.
